scholarly journals Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia

2008 ◽  
Vol 22 (24) ◽  
pp. 3403-3408 ◽  
Author(s):  
M. G. Guenther ◽  
L. N. Lawton ◽  
T. Rozovskaia ◽  
G. M. Frampton ◽  
S. S. Levine ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mixed Lineage Leukemia ◽  
Genes Encoding

scholarly journals The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis

2017 ◽  
Vol 10 (1) ◽  
Author(s):  
Lina Yang ◽  
Li Liu ◽  
Hong Gao ◽  
Jaya Pratap Pinnamaneni ◽  
Deepthi Sanagasetti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Stem Cell Factor ◽  
Transcriptional Regulator ◽  
Mixed Lineage Leukemia

scholarly journals Deletion of the NF-κB subunit p65/RelA in the hematopoietic compartment leads to defects in hematopoietic stem cell function

Blood ◽  
2013 ◽  
Vol 121 (25) ◽  
pp. 5015-5024 ◽  
Author(s):  
Sarah J. Stein ◽  
Albert S. Baldwin
Keyword(s):  
Stem Cell ◽  
Hematopoietic Stem Cell ◽  
Cell Function ◽  
Lineage Commitment ◽  
Key Factors ◽  
Cell Homeostasis ◽  
Hematopoietic Stem ◽  
Expression Of Genes ◽  
Key Points ◽  
Genes Encoding

Key Points p65 is an important factor in hematopoiesis through the regulation of hematopoietic stem cell function and lineage commitment. p65 controls the expression of genes encoding key factors that promote hematopoietic stem cell homeostasis.

scholarly journals Inhibition of histone methyltransferase EZH 2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16

2014 ◽  
Vol 105 (5) ◽  
pp. 512-519 ◽  
Author(s):  
Koki Ueda ◽  
Akihide Yoshimi ◽  
Yuki Kagoya ◽  
Satoshi Nishikawa ◽  
Victor E. Marquez ◽  
...  
Keyword(s):  
Stem Cell ◽  
Histone Methyltransferase ◽  
Mixed Lineage Leukemia ◽  
Leukemia Stem Cell ◽  
Mixed Lineage Leukemia Fusion

Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)–rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study

Blood ◽  
2010 ◽  
Vol 116 (15) ◽  
pp. 2644-2650 ◽  
Author(s):  
Georg Mann ◽  
Andishe Attarbaschi ◽  
Martin Schrappe ◽  
Paola De Lorenzo ◽  
Christina Peters ◽  
...  
Keyword(s):  
Stem Cell ◽  
Acute Lymphoblastic Leukemia ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
Lymphoblastic Leukemia ◽  
Mixed Lineage Leukemia ◽  
Hematopoietic Stem ◽  
Significant Difference

AbstractTo define a role for hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia and rearrangements of the mixed-lineage-leukemia gene (MLL+), we compared the outcome of MLL+ patients from trial Interfant-99 who either received chemotherapy only or HSCT. Of 376 patients with a known MLL status in the trial, 297 (79%) were MLL+. Among the 277 of 297 MLL+ patients (93%) in first remission (CR), there appeared to be a significant difference in disease-free survival (adjusted by waiting time to HSCT) between the 37 (13%) who received HSCT and the 240 (87%) who received chemotherapy only (P = .03). However, the advantage was restricted to a subgroup with 2 additional unfavorable prognostic features: age less than 6 months and either poor response to steroids at day 8 or leukocytes more than or equal to 300 g/L. Ninety-seven of 297 MLL+ patients (33%) had such high-risk criteria, with 87 achieving CR. In this group, HSCT was associated with a 64% reduction in the risk of failure resulting from relapse or death in CR (hazard ratio = 0.36, 95% confidence interval, 0.15-0.86). In the remaining patients, there was no advantage for HSCT over chemotherapy only. In summary, HSCT seems to be a valuable option for a subgroup of infant MLL+ acute lymphoblastic leukemia carrying further poor prognostic factors. The trial was registered at www.clinicaltrials.gov as #NCT00015873 and at www.controlled-trials.com as #ISRCTN24251487.

scholarly journals Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential

2011 ◽  
Vol 19 (3) ◽  
pp. 428-439 ◽  
Author(s):  
J M Heddleston ◽  
Q Wu ◽  
M Rivera ◽  
S Minhas ◽  
J D Lathia ◽  
...  
Keyword(s):  
Stem Cell ◽  
Mixed Lineage Leukemia ◽  
Glioma Stem Cell ◽  
Tumorigenic Potential

Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells

Blood ◽  
2011 ◽  
Vol 117 (23) ◽  
pp. 6304-6314 ◽  
Author(s):  
Shunya Arai ◽  
Akihide Yoshimi ◽  
Munetake Shimabe ◽  
Motoshi Ichikawa ◽  
Masahiro Nakagawa ◽  
...  
Keyword(s):  
Gene Expression ◽  
Stem Cells ◽  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Hematopoietic Stem Cells ◽  
Myeloid Leukemia ◽  
Mixed Lineage Leukemia ◽  
Aberrant Expression ◽  
Hematopoietic Stem ◽  
Acute Myeloid

Abstract Ecotropic viral integration site-1 (Evi-1) is a nuclear transcription factor that plays an essential role in the regulation of hematopoietic stem cells. Aberrant expression of Evi-1 has been reported in up to 10% of patients with acute myeloid leukemia and is a diagnostic marker that predicts a poor outcome. Although chromosomal rearrangement involving the Evi-1 gene is one of the major causes of Evi-1 activation, overexpression of Evi-1 is detected in a subgroup of acute myeloid leukemia patients without any chromosomal abnormalities, which indicates the presence of other mechanisms for Evi-1 activation. In this study, we found that Evi-1 is frequently up-regulated in bone marrow cells transformed by the mixed-lineage leukemia (MLL) chimeric genes MLL-ENL or MLL-AF9. Analysis of the Evi-1 gene promoter region revealed that MLL-ENL activates transcription of Evi-1. MLL-ENL–mediated up-regulation of Evi-1 occurs exclusively in the undifferentiated hematopoietic population, in which Evi-1 particularly contributes to the propagation of MLL-ENL–immortalized cells. Furthermore, gene-expression analysis of human acute myeloid leukemia cases demonstrated the stem cell–like gene-expression signature of MLL-rearranged leukemia with high levels of Evi-1. Our findings indicate that Evi-1 is one of the targets of MLL oncoproteins and is selectively activated in hematopoietic stem cell–derived MLL leukemic cells.

scholarly journals Clinical significance of CD7-positive stem cell leukemia. A distinct subtype of mixed lineage leukemia

Cancer ◽  
1991 ◽  
Vol 68 (10) ◽  
pp. 2273-2280 ◽  
Author(s):  
Keiko Yumura-Yagi ◽  
Junichi Hara ◽  
Hiroki Kurahashi ◽  
Jun Okamura ◽  
Shoichi Koizumi ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Significance ◽  
Mixed Lineage Leukemia ◽  
Cell Leukemia ◽  
Distinct Subtype ◽  
Stem Cell Leukemia
Sign in / Sign up

Export Citation Format

Share Document